Handelsbanken Fonder AB lessened its stake in shares of STAAR Surgical (NASDAQ:STAA – Get Rating) by 22.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,100 shares of the medical instruments supplier's stock after selling 2,100 shares during the quarter. Handelsbanken Fonder AB's holdings in STAAR Surgical were worth $567,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Raymond James & Associates lifted its holdings in shares of STAAR Surgical by 96.4% during the first quarter. Raymond James & Associates now owns 12,704 shares of the medical instruments supplier's stock valued at $1,015,000 after acquiring an additional 6,234 shares during the period. WINTON GROUP Ltd boosted its position in STAAR Surgical by 41.3% in the first quarter. WINTON GROUP Ltd now owns 3,307 shares of the medical instruments supplier's stock valued at $264,000 after buying an additional 966 shares in the last quarter. GSA Capital Partners LLP grew its stake in STAAR Surgical by 200.0% during the first quarter. GSA Capital Partners LLP now owns 10,155 shares of the medical instruments supplier's stock worth $811,000 after buying an additional 6,770 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of STAAR Surgical by 815.0% during the first quarter. Meeder Asset Management Inc. now owns 1,345 shares of the medical instruments supplier's stock worth $107,000 after buying an additional 1,198 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of STAAR Surgical by 18.8% in the first quarter. Principal Financial Group Inc. now owns 405,810 shares of the medical instruments supplier's stock valued at $32,428,000 after acquiring an additional 64,087 shares during the last quarter. Institutional investors and hedge funds own 96.38% of the company's stock.

STAAR Surgical Stock Down 0.6 %

STAA stock opened at $94.59 on Thursday. STAAR Surgical has a twelve month low of $49.03 and a twelve month high of $163.08. The company has a market cap of $4.54 billion, a P/E ratio of 141.18 and a beta of 1.09. The business's fifty day moving average is $84.34 and its 200-day moving average is $73.05.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Canaccord Genuity Group increased their price target on STAAR Surgical from $89.00 to $97.00 in a research report on Thursday, August 11th. Needham & Company LLC upped their price target on shares of STAAR Surgical from $87.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. BTIG Research raised their price objective on shares of STAAR Surgical from $98.00 to $103.00 in a research report on Thursday, August 11th. Jefferies Financial Group reduced their target price on shares of STAAR Surgical from $165.00 to $125.00 in a research report on Thursday, August 11th. Finally, Benchmark raised their price target on shares of STAAR Surgical from $97.00 to $117.00 and gave the company a "buy" rating in a report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $106.83.

Insider Buying and Selling

In related news, CTO Keith Holliday sold 16,582 shares of the company's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $106.29, for a total value of $1,762,500.78. Following the completion of the transaction, the chief technology officer now directly owns 19,437 shares of the company's stock, valued at approximately $2,065,958.73. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by company insiders.

About STAAR Surgical

(Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Stories

• Get a free copy of the StockNews.com research report on STAAR Surgical (STAA)
• Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
• Is World Wresting Entertainment Getting Ready to Be Sold?
• 3 Materials Stocks That May Earn a Place on Your Watchlist
• Crowdstrike Stock Retraces, As Earnings Sober Expectations
• Will The Institutions Buy The Dip In Ambarella Stock?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.